TABLE 15.

Antenatal Deworming

SourceLocation and Type of TrialInterventionMaternal OutcomePerinatal/Neonatal Outcome
Abel et al297India; rural setting; PCSIron supplementation and deworming were provided to all pregnant women in the intervention area (n = 458) from the fourth month of pregnancy. An intensive information, education, and communication effort was carried out that provided facts on anemia and diet modification to each pregnant woman, using a 1-to-1 approach in the community, and a group method in the mobile clinics. This was carried out for a period of 18 mo. Pregnant controls in a neighboring village (n = 387) received only the previously available standard of care.A significant decrease in the prevalence of anemia was found, from 56% to 25% (P < .001), 73% to 49% (P < .001) and 69% to 57% (P < .01) among women treated from the first, second and third trimesters, respectively, in the intervention area. Significant (P < .001) increases of 0.85 g/dL in mean Hb level (CI: 0.79–0.91), 0.59 g/dL (CI: 0.57–0.61) and 0.36 g/dL (CI: 0.32–0.40) were also observed in treated women in the first, second and third trimesters, respectively.
De Silva et al299Sri Lanka; urban hospital setting; retrospective cohort study (RCS)All women recruited (n = 7087) were questioned directly about their use of antihelminthics during that pregnancy. 5275 had taken mebendazole and 1737 had not taken antihelminthics and were in the control group.The stillbirth, PMRs and VLBW rates were 45%, 45% (P = .004) and 53% (P = .003) lower, respectively, among the women who took mebendazole during pregnancy.
Atukorala et al167See Table 7
Christian et al300Nepal; rural setting; PCSPregnant women received 1 of 5 groups of multinutrient supplements, some of which contained albendazole doses. Women who received albendazole during the second trimester were compared to women who did not receive albendazole.NMR of infants born to women treated with albendazole compared to those born to controls declined by 46% (RR: 0.54; CI: 0.37–0.78).